Life Sciences Archive » November, 2018

Life Sciences - November, 2018

265 articles

• Class Action Rule Changes Target 'Professional Objectors'
• Immunotherapy Co. Hits Ch. 11 With $21M In Debt
• 11th Circ. OKs Indictment Change In Med-Smuggling Case
• Medtronic Owes Ind. Surgeon $112M In Royalties, Jury Finds
• Aralez Creditors Slam Proposed Ch. 11 Sales To Deerfield
• Fed. Circ. Won't Shield Atty Emails For Thermo Fisher Unit
• DOJ Will Nuke Gilead FCA Suit, Supreme Court Hears
• 8 Firms To Guide 4 IPOs Led By $500M Biotech Deal
• Pa. Judge Won't Revive Xarelto Suit Despite Patient's Death
• Monsanto Objects To Dying Man's Bid For A Quick Trial
• Becton Buyers' Antitrust Suit Killed Under Illinois Brick
• Société Générale: Sanctions Enforcement Is Alive And Well
• Gov't Wants Insys Founder's Atty Sanctioned For Media Talk
• Health Hires: Foley, Smith Gambrell, NewYork-Presbyterian
• What High Court Will Consider In Helsinn On-Sale Bar Case
• Dickinson Wright Nabs 6 IP Attys In Florida, Calif., DC
• Mass. US Atty Sends Warnings To Opioid-Prescribing Docs
• Fund Manager Tries To Duck Valeant Insider Trading Claims
• Pfizer Loses PTAB Challenge To Antibody Drug Patents
• Fla. Pharmacist Gets 6½ Years For Bogus Claims For Creams
• Pet Med Distributors Can't Access PetIQ's Merger Filings
• PTAB Upholds Patent For Akorn Glaucoma Drug Zioptan
• Sterigenics Suits Belong In State Court, Ill. Residents Say
• Insys Founder Must Turn Over Docs In Opioid Probe, Feds Say
• 5 Mos. Sought For Biotech Exec Who Pled Guilty After Mistrial
• JPML Wary Of Special Litigation For 'Opioid Babies'
• New CMS Rules Reinforce Trend Away From Traditional Care
• In Hip Implant MDL, Preemption Cuts Across State Lines
• 3rd Circ. Upholds Case Transfer Limits On Bankruptcy Courts
• Mylan Asks Supreme Court To Rein In 'Tactical' Drug Patenting
• Ex-Zimmer Exec Loses Benefits Bid In Sex Discrimination Suit
• 2 Attys Charged, Face SEC Suit Over Pump & Dump Scheme
• Mylan Pushes For Consumer Witnesses In Battle With Celgene
• AbbVie Tries To Ax Investor Suit Over $100M Stock Drop
• Deals Rumor Mill: Sears, Murphy Oil, GSK
• Med Tech Co. Seeks DC Circ. Review Of $400M Award Denial
• Drug Co. Can't Duck Opioid Questions In Pay-For-Delay Suit
• FDA Approves First Non-Hodgkin's Lymphoma Biosimilar
• Goodwin-Led Biotech Co. Moderna Sets Sights On $500M IPO
• Merck Tells Justices Misconduct Doesn't Nix $200M IP Award
• Full Fed. Circ. Asked To Skip 'Blocking Patent' Case
• Insys Ex-VP To Cooperate With Gov't In Opioid Kickback Case
• Eli Lilly Wins Stay In Eagle Antitrust Suit Amid Patent Fight
• HHS OIG Opinion Raises Questions On Free Drug Offers
• DLA Piper Fights DQ Bid In Hemophilia Treatment Row
• Justices Weigh Missed Deadline In Nutraceutical False Ad Suit
• Phigenix Fights $2.2M Atty Fee Bid In Cancer Drug IP Row
• FDA Focus: What Arnold & Porter's Practice Chair Is Watching
• WARF Hit With $32M Bill Over WashU Royalty Sharing
• Biotech Co. Nuredis Sued Over Board Members' Legal Costs
• 3rd Circ. Says Doc's TCPA Claims Against Sanofi Are Untimely
• Express Scripts Urges Toss Of Records Fee Suit
• Irish Genomics Research Co. Inks $400M Investment
• Jurors Should Ask More Questions During Trials
• The Narrow Meaning Of Asacol Class Action Ruling
• 9th Circ. Won't Revisit FCA Materiality Dispute
• ​​​​​​​Big Pharma Howls As Feds Eye Wider Drug Negotiations
• Cloud Co. Can't Beat Suit Over Drug-Testing Software IP
• 32 States Back Ark. In Potential High Court Drug-Price Fight
• Federal Insurance Beats Suit Over Denial Of Life Policy Claim
• Ex-PTAB Chief Fires Back At Medtronic In Gay Bias Case
• Deals Rumor Mill: Bayer, Fiat, Total
• Forward Seeks 2nd Fed. Circ. Look At MS Drug Patent Case
• FDA Modernizes Medical Device Review Process
• DLA Piper Nabs Life Sciences Pro From Goodwin
• Calif. Ruling Dings Engagement Letter Arbitration Clauses
• Pa. Mesh Judge Won't Recuse Over Mom's Case Against J&J
• 10 Things We Wish We Were Told When Going In-House
• California Tax Takes: Tax Ballot Initiative Constitutionality
• Fed. Circ. Is Tightening Appellate Standing For IPR Cases
• Law360 MVP Awards Go To Top Attorneys From 71 Firms
• Perrigo Wants To Nix Investor Suits Over Failed Mylan Buyout
• UK Co. Says Abbott Can't Tie It To 'Gray Market' Scheme
• Rite Aid Escapes Generic Drug Copay Suit Over Timeliness
• FDA Finally Hitting Sweet Spot With Off-Label Oversight
• Drug Cos. Hit With $18M False Ad Verdict Over Probiotic IP
• Drug Cos. Can't Block Damages In Opioid MDL Bellwethers
• Janssen Turns To High Court In Bid To Block Zytiga Generics
• Consumer Groups Push 1st Circ. To Redo Asacol Class Cert.
• Taxation With Representation: Latham, Wachtell, Kirkland
• More Medical Device Co. Inspections Upped Compliance: FDA
• Sanofi Tells Justices To Pass On Appeal Over Repatha IP
• 3 Firms Vie To Lead Class Suit Over Alleged AbbVie Kickbacks
• Up Next At High Court: Apple's App Store, Civil Forfeiture
• Taiwanese Biotech Tops 3 IPOs Totaling $46M In Short Week
• The Virtual Law Team: Advantages For Litigants And Lawyers
• Deals Rumor Mill: Carlyle, Lumenis, Babytree Group
• Teva Execs Liable For Price-Hike Misstatements: Investors
• Why Biotech And Pharma Patents Survive IPR
• What Does A Split Congress Mean For Drug Pricing Agenda?
• Dr. Reddy's, Mylan Win Challenge To Arthritis Drug Patents
• Fed. Circ. Says Analysis Lacking In Nix Of Quillivant IP
• J&J Again Asks Pa. Mesh Judge To Recuse Over Family Ties
• Pension Fund Slams Firm's Bid To Shed Valeant Fraud Suit
• Fed. Circ. Lifts Block On Dr. Reddy's Suboxone Generic
• $16M Deal OK'd In Zicam Cold Meds False Ad Class Suit
• Feds Want At Least 5 Yrs For Pharma CEO's $2M Drug Fraud
• Tokai Investor Marks Underwriters Liable In $10.8M Suit
• Breast Implant CEO Slams SEC's Stock Fraud 'Scheme' Claim
• Ex-Aveo CFO Found Liable For Misleading Investors
• GSK, Ex-Workers Battle For Quick Wins In Severance Fight
• Former Teva Exec Nabs $6.2M Bias Verdict After Firing
• EU Approves Takeda's £46B Shire Deal With Drug Sale
• Smith & Nephew Ditches Untimely Hip Implant Cases In MDL
• Fed. Circ. Won't Revisit Whether Catalog Dooms Dental Patent
• Saul Ewing Adds IP, Life Sciences Partners In Boston
• Shearman & Sterling Reps Boston Scientific In £3.3B BTG Buy
• Emerging Cybersecurity Threats In The Legal Industry
• Mallinckrodt Urges Court To Toss Investor Suit Over Acthar
• Free Mallinckrodt Drugs Risk Kickback Fines, Watchdog Says
• Justices Won't Hear Challenge To Fed. Circ. Drug Patent Test
• New Express Scripts Policy Merits Suit Revival, Court Told
• Blood-Clot Drug Buyers Seek Class Cert. In Antitrust Suit
• States, Feds Debate Birth Control Mandate Row's Next Step
• 4 Cos. Eye December IPOs With New Filings Totaling $350M
• Bankrupt Aralez Can Pay Execs Up To $4M In Work Bonuses
• Kirkland, Simpson Steer $3.15B Colfax-DJO Global Deal
• Pharma Cos. Sued Over Children Born Addicted To Opioids
• PTAB Invalidates Antecip's Bone Treatment Patent
• Medtronic Unit Agrees To $54.5M Deal In Investor Fraud Suit
• Accountant Denied Retrial Over $18M Biotech VC Fraud
• Supreme Court Will Address FCA Statute Of Limitations
• Rise Of The CMOs
• Alaska Native Health Group Added To Massive Opioid Suit
• Health Hires: Quinn Emanuel, Goodwin, Ropes & Gray
• Texas Man Convicted In $36M Drug Resale Scheme
• Deals Rumor Mill: Tesaro, Eli Lilly, Technicolor
• Can Canadians Enter US For Cannabis-Related Business?
• Calif. Judge Moves Up Roundup Trial Due To Health Concerns
• Goodwin Taps Ex-Gunderson Pro With Capital Markets Chops
• 2nd Mistrial Called On Claims J&J Talc Gave Atty Fatal Cancer
• Inside Trader Avoids Prison Time After Aiding Feds
• Pharma Cos. Must Hand Over Generic Restasis Plans In MDL
• Judge Won't Quash AGs' Subpoenas In Generic Pricing MDL
• Deals Rumor Mill: Centrexion, Dayco, JD Group
• Insys Sales VP To Plead Guilty In Opioid Kickback Case
• A Chat With Bryan Cave Innovation Chief Katie DeBord
• FDA Streamlines 510(k) Process, As Courts Reconsider It
• J&J Should Pay For Talc Devotee's Death, SC Jury Hears
• 9th Circ. Judge Doubts Bio-Rad Appeal Of Ex-GC's $11M Win
• Gibson Dunn Bows Out Of Pharma RICO Suit Amid DQ Bid
• Pfizer Debuts Biosimilar Of Amgen, Janssen Meds
• J&J Staves Off Asbestos Baby Powder Suit In Calif. Jury Win
• FTC Shuts Down 1-800 Contacts Online Ad Compacts
• Fed Circ. Won't Stay Immunity Ruling For Allergan's Appeal
• Bio-Rad Wins $24M Jury Verdict In 10X Genomics Patent Suit
• Pa. Panel Urged To Revive Risperdal Breast-Growth Case
• When A Patent Disclosure Is Not A Disclosure
• Ranbaxy Consumers Denied Cert. In Drug Contamination Suit
• Aveo CFO Testifies He Had Support For Disclosure Decisions
• Ropes & Gray Steers Medical Device Co.'s $56M IPO
• Allergan Cuts A Few State Claims In Restasis MDL
• Simple Secrets For Improving Your CLE
• 10 Firms Vie For Lead Counsel In Opko Health Fraud Row
• Express Scripts, Pharmacy Drama Ends With Last-Minute Deal
• Gottlieb Says FDA Acted Slowly On Opioids
• Imprimis Gets $100K Knocked Off Allergan Sanctions Bill
• Pharma Co. Shakes Texas Securities Suit In Post-Cyan Ruling
• Janssen 'Doublespeak' Fueled Opioid Crisis, NJ Suit Says
• Fed. Circ. Won't Restore Allergan's Restasis Patent Claims
• Teva Can't Escape Suit Over Price-Hike Statements: Investors
• Aveo Withheld FDA Rec From Investors, Ex-CFO Testifies
• Ex-CEO Accused Of Tipping Oriole Reaches $1.5M SEC Deal
• Investors Reach $12M Deal In Biotech Stock-Drop Case
• Ex-Merrimack Analyst Gets 6 Months For Insider Trading
• FDA Warns Stem Cell Co. On Marketing, Manufacturing
• AstraZeneca Inks $1.5B Sale Of US Respiratory Drug Rights
• It's Time For Law Firms To Start Talking About Gen Z
• Trump Picks Regulatory Czar For Kavanaugh's DC Circ. Seat
• Should Juries Try To Predict FDA Drug Labeling Decisions?
• Justices Won't Hear Cert. Dispute In Vitamin E Labeling Suit
• Fed. Circ. Tells PTAB To Look At NuVasive Patent Again
• Options Broker Must Stay In TIAA-Led Class In Valeant Suit
• Deals Rumor Mill: BlackBerry, Permira, ADM
• Express Scripts Rightfully Nixed Pharmacy Contract
• Judge OKs Release Of Market Share Data In Opioid MDL
• SEC Fights Priest's Bid To Skip $1.3M Short-Selling Suit
• Sens. Seek White House Backing For Pay-For-Delay Drug Bill
• 10 Firms To Guide 6 IPOs Exceeding $800M
• A Post-Election Survey Of The Health Care Ecosystem
• Homeopathic Co. Beats Consumer's Sugar Pill Claims
• Pharmaceutical Warnings: A Changing Landscape
• What To Expect From New Democratic Investigation Efforts
• Helsinn Tells Justices Teva 'Badly Misconstrues' On-Sale Bar
• New J&J Pelvic Mesh Trial Ordered In Pa.
• Anixa Investor Sues In Chancery Alleging Insider Stock Moves
• Del. Jury Finds Flexus Took Incyte Secrets, Nixes Damages
• Exforge Deal 'More Pernicious' Than Actavis, Court Told
• Back To School: Yale's Linda Greenhouse Talks Journalism
• Cooley Can Stay In Trade Secrets Suit Over Genomics Data
• McCarter & English Adds IP Duo In Boston
• Celebrate Veterans By Improving Their Access To Justice
• Blood-Pressure Drug Cos. Hit With Suit Over Contamination
• Patent And Copyright Changes In The New NAFTA
• Calif. Appeals Panel Revives Suits Over Diabetes Drugs
• Gibson Dunn Must Comply With Subpoena, Al Jazeera Says
• Fed. Circ. Upholds PTAB Nix Of Blood-Clotting Patent
• Investors Sue Akorn After Failed Merger 'Debacle' Kills Stock
• Medicaid Rebate Suit Not Barred By Similar Suits: Ex-Exec
• Biopharma Co. Hit With Suit Over Directors' 'Excessive' Pay
• Local Gov'ts Press For Opioid Market Share Data
• Fresenius Bid To Save Diprivan Patent Denied By Fed. Circ.
• Ranbaxy Abused Generic Drug Application Process, Suit Says
• Pharma Biz Nabs $120M For Liver Disease Drug Development
• Investors Sue Infertility Co. OvaScience To Stop Merger Plan
• World Wide Weed: Best Practices For Internet Cannabis Ads
• When Regulatory Standards And Truth In Advertising Collide
• Time To Reclaim Wellness For All Lawyers
• Kavanaugh Fallout Fuels GOP's Senate Expansion
• Dems Pump Brakes On Trump Agenda With House Win
• Senate Republican Win Cements Trump's Judicial Makeover
• Voting Machine Critics Tout Low-Tech Fix For Hacking Fears
• FDA Warning Wire: No Risk Info On Drug Webpage
• Express Scripts Defends Fee Ask After Pharmacy Sanctioned
• Fresenius Fights Kyle Bass Diprivan Challenge At Fed. Circ.
• Endocyte's $2.1B Sale To Novartis 'Unfair' To Investors: Suit
• Fed. Circ. Urged Not To Stay Immunity Ruling For Appeal
• Orencia Patent Appeal Not Moot, Momenta Tells Fed. Circ.
• Insurer Needn't Cover Landlord In Suit Over CO Leak
• Aveo CFO Told Investors 'Half The Story,' Jury Hears
• DST Hit With ERISA Suit Over Valeant Stock Drop
• 1st Circ. Mulls Boston NPR Push For Release Of Juror IDs
• J&J Talc Caused Atty's Fatal Mesothelioma, 2nd Jury Hears
• Jury Award Doubled To $268M In Hearing Aid IP Case
• Invisalign Maker Says Rival Is Infringing Scanner Cover IP
• Ex-Akebia Statistician Gets 3 Years For Insider Trading
• Deals Rumor Mill: Sears, Tata, Medacta
• Humana Seeks Case's Inclusion In Generic Price-Fixing MDL
• Opioid Distributors Seek Ohio High Court Input On State Law
• Teva Suit Built On 'Tottering Tower Of Conjecture,' FDA Says
• Key Figure Gets Prison For $3M Insider Trading Scheme
• Vet Products Co. To Pay $6.75M Over Unwanted Faxes
• Software Startup Leads 3 IPO Launches Totaling $535M
• Jury Picked For Ex-Drug Co. CFO's Securities Fraud Trial
• Fears Nachawati Adds Ex-DOJ Opioid Specialist In Dallas
• Supreme Court Rejects Ex-InterMune CEO's Conviction Appeal
• Medtronic Fires Back In Ex-PTAB Chief's Gay Bias Suit
• Boies Schiller Stuck On Express Scripts Breach Trial
• Roundup Verdict Points To Jury Realities In Product Cases
• Spotlight On Private Antitrust Enforcement At Seoul Forum
• 3 Firms Lead Pack In Rocky October For IPOs
• Hagens Berman Seeks Lead Role In Intuniv Pay-For-Delay Suit
• DaVita Settles After $384M Verdict In Patient Danger Suits
• Pa. Panel Won't DQ Goodwin Procter In Teva Coverage Row
• Pharmacy Co. Slams EHealthline's Bid To Pause $3.5M Award
• Zetia MDL Buyers Maintain Merck's Generic Deal Was Illegal
• Damages Forfeited In Opioid MDL Bellwethers, Drug Cos. Say
• Ex-Genentech Engineer Pleads Not Guilty To Hacking, IP Theft
• Settlement Reached In Stryker Hip Replacement Suits
• NJ Court Kicks Stendra Patent Case To Texas
• What We Heard At The FTC Hearings: Days 6 And 7
• Pa. Justices Urged To Reject Limit On Risperdal Suit Window
• Deals Rumor Mill: Pfizer, Apple, Ping An
• Covington Advises Illumina's $1.2B Pacific Biosciences Buy
• Celgene's Bid To Trim Drug Monopoly Suit Denied
• Trump's Point Person On Drug Prices Dies
• PTAB Says Rituxan Patent Challenged By Pfizer Is Obvious
• Aveo Stock Plunge Fair Game When Ex-CFO Stands Trial
• Boies Schiller Can't Ditch Clients Before Trial: Express Scripts
• Sanofi Wants Claims Against Mylan Out Of EpiPen MDL
• Pharma Co. Cleared To Use Lender Cash In Ch. 11
• AbbVie Looks To Ditch FCA Suit Alleging Humira Kickbacks
• FDA Steps Up Its Focus On Medical Device Cybersecurity
• CMS Drug Price Proposal Would Harm Patients, Providers
• Jenner, Gibson Guide $630M Sale Of Water Co. To PE Shop